Atyr_Logo.png
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
06 mars 2025 16h02 HE | aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Atyr_Logo.png
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
04 mars 2025 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
Atyr_Logo.png
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
24 févr. 2025 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
Atyr_Logo.png
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
29 janv. 2025 08h00 HE | aTyr Pharma, Inc.
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025...
Atyr_Logo.png
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
17 déc. 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Atyr_Logo.png
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
12 déc. 2024 16h00 HE | aTyr Pharma, Inc.
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
Atyr_Logo.png
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
10 déc. 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Atyr_Logo.png
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
09 déc. 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
Atyr_Logo.png
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
15 nov. 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
Atyr_Logo.png
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
07 nov. 2024 16h01 HE | aTyr Pharma, Inc.
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update